New York-based ProofPilot was launched in 2014 to make clinical trials easier to set up and run not to mention elicit participation by making them fun. With ProofPilot anyone can design a research study (you don’t have to be a PhD)! Now with more rigorous studies, we get more and better answers that improve our healthcare—based on evidence. ProofPoint is privately held and has raised at least $1.85 million in venture funding from CueBall Capital and Brooklyn Bridge Ventures.
TrialSite talks to ProofPilot’s Matthew Amsden about all of that and much more. You can learn more about ProofPilot and Matthew Amsden below:
Read more here on TrialSite News